Pinitol - Humanetics

Drug Profile

Pinitol - Humanetics

Alternative Names: Cerebrate; NIC 515

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Mount Sinai School of Medicine
  • Developer Humanetics Corporation
  • Class Antidementias; Antihyperglycaemics; Insulin sensitisers; Nootropics; Small molecules; Sugar alcohols
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 19 Jun 2015 Pinitol is still in phase-II development for Alzheimer's disease in USA
  • 02 Jun 2012 Phase IIb development is ongoing in USA
  • 12 Apr 2010 Humanetics completes a phase IIa trial (NCT00470418) in Alzheimer's disease in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top